Psoriasis Treatment Center of Central New Jersey

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Psoriasis Treatment Center of Central New Jersey sits in the top decile of US sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count).

16 total trials 8 currently recruiting 7 completed later-stage tilt top decile by trial count

Psoriasis Treatment Center of Central New Jersey: 16 sponsored US clinical trials, 8 recruiting.

Psoriasis Treatment Center of Central New Jersey sponsors 16 registered US clinical trials on ClinicalTrials.gov, 8 of them currently recruiting, and 7 completed. 14 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Psoriasis, with 5 trials.

Top-decile sponsor footprint

Psoriasis Treatment Center of Central New Jersey ranks in the top decile of sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

16 total, page 1 of 1

RECRUITING Phase 4

Upadacitinib for Prurigo Nodularis

NCT06773403

RECRUITING Phase 4

Cryotherapy in Combination with Red Light PDT for Actinic Keratosis of Full Face

NCT06745999

RECRUITING Phase 4

Dupixent and Narrowband UVB for Atopic Dermatitis

NCT05285839

RECRUITING Phase 4

Taltz in Combination With Enstilar for Psoriasis

NCT04372277

RECRUITING Phase 4

ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.

NCT04347473

RECRUITING Phase 4

Duobrii in Combination With Biologics

NCT04119102

RECRUITING Phase 4

Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

NCT03827876

RECRUITING NA

An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients

NCT03392337

ACTIVE NOT RECRUITING Phase 4

Tralokinumab for Dupilumab Failures

NCT06773455

COMPLETED Phase 4

Vtama in Psoriasis Patients Being Treated With Biologics.

NCT06103695

COMPLETED Phase 4

Combination of Sotyktu and Enstilar for Plaque Psoriasis

NCT06329258

COMPLETED

An Outcomes Study to Determine the Reasons Patients on Biologic Therapy Discontinue Treatment and Fail to Follow-up With Their Providers

NCT03964168

COMPLETED Phase 4

Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis

NCT03587194

COMPLETED Phase 4

Enstilar in Combination With Biologic Agents

NCT03080545

COMPLETED Phase 4

Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray

NCT02985736

COMPLETED Phase 4

Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis

NCT02412644

Phase Distribution

PhaseTrial count
Phase 4 14

Where Psoriasis Treatment Center of Central New Jersey enrollment is open (later-stage tilt)

8 recruiting of 16 indexed (50% open); 7 completed (44%).

Phase mix: 14 late (III/IV) vs 0 early (I/II) (later-stage heavy).

Top condition: Psoriasis (5 trials), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Psoriasis Treatment Center of Central New Jersey: open-pipeline peers nationwide

Peers matched on 16 registered trials and 50% open enrollment, not the therapeutic-area sidebar.

Psoriasis Treatment Center of Central New Jersey sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05101520 0%20%40%60% Total trials Recruiting share Psoriasis Treatment Center of Central New JerseyAccelerated Community Oncology Research NetworkAltimmuneAmerican UniversityAnthera Pharmaceuticals1200 Pharma1ST Biotherapeutics3ive Labs60 Degrees Pharmaceuticals
Psoriasis Treatment Center of Central New Jersey sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Psoriasis Treatment Center of Central New Jersey sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 16 trials (± recruiting share)

Sponsors near 50% open enrollment (± trial volume)

What to do with this Psoriasis Treatment Center of Central New Jersey page

16 registered trials is a research-attention snapshot, not an endorsement of Psoriasis Treatment Center of Central New Jersey or any single study.

  • 8 of Psoriasis Treatment Center of Central New Jersey's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Psoriasis is the condition Psoriasis Treatment Center of Central New Jersey studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Psoriasis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Psoriasis Treatment Center of Central New Jersey pipeline card: 16 registered trials from official public datasets.Report a data error.